| | • 1 | · / | |
|---|-----|--------|---|
|] | | , | |
|] | | | |
|] | | | HEALTH AND SAFETY PLAN |
| | | | CORKTOWN DEVELOPMENT – AREA 4 1336 AND 1342-1350 BAGLEY STREET |
|] | | | DETROIT, WAYNE COUNTY, MICHIGAN |
|] | | | |
| | | | Project No. RM042764-004 |
| | | | |
| | | | |
| | | | October 24, 2005 |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | The Traverse Group 7451 Third Street |
| | | | Detroit, Michigan 48202 (313) 871-5800 |
| | | | THE |
| Π | | | THE TRAVERSE GROUP |

HEALTH AND SAFETY PLAN CORKTOWN DEVELOPMENT – AREA 4 1336 AND 1342-1350 BAGLEY STREET DETROIT, WAYNE COUNTY, MICHIGAN

TABLE OF CONTENTS

| EMER | GENCY CONTACT INFORMATION | i |
|-------------|---|--------------|
| HOSP | TAL INFORMATION | i |
| | Location of Local Hospital | ital i ii |
| 1.0 | INTRODUCTION | 1 |
| 2.0 | SITE DESCRIPTION | |
| | 2.1 Chemical and Physical Hazards2. Affected Area | |
| 3.0 | ON-SITE ORGANIZATION AND COORDINATION | 2 |
| 4.0 | PERSONNEL TRAINING | 2 |
| 5.0 | SITE CONTROL | 2 |
| | 5.1 Exclusion Zone | 3 |
| 6.0 | ENVIRONMENTAL MONITORING | 3 |
| 7.0 | PERSONAL PROTECTIVE EQUIPMENT | 4 |
| | 7.1 Exclusion Zone | |
| 8.0 | EMERGENCY PROCEDURES | 5 |
| 9.0 | ACKNOWLEDGMENT | 7 |

TABLES

Table 1 Chemical Hazard Summary



HEALTH AND SAFETY PLAN CORKTOWN DEVELOPMENT – AREA 4 1336 AND 1342-1350 BAGLEY STREET DETROIT, WAYNE COUNTY, MICHIGAN

EMERGENCY CONTACT INFORMATION

| EMERGENCY | ORGANIZATION/AGENCY | EMERGENCY NUMBER |
|------------------|--|-------------------------------|
| Injury | United Community Hospital 2401 20 th Street, Detroit | 313-964-4422 |
| Ambulance | Dispatched through 9-1-1 | EMERGENCY: 9-1-1 |
| Fire | Detroit Fire Department | EMERGENCY: 9-1-1 |
| | | Non-Emergency: (313) 596-2900 |
| Police | Detroit Police Department | EMERGENCY: 9-1-1 |
| | | Non-Emergency: (313) 224-3000 |

HOSPITAL INFORMATION

Location of Local Hospital


The nearest hospital is the United Community Hospital, located at 2401 20th Street, Detroit, Michigan.

Directions from Corktown Development - Area 4 Site to United Community Hospital

Head northeast on Bagley Street, towards Brooklyn Street. Turn left onto Brooklyn Street. Turn left onto Michigan Avenue, proceed for approximately one mile. Turn left onto 20th Street; proceed for less than 0.1 mile. End at United Community Hospital.




Hospital Route Map





Site Location Map





HEALTH AND SAFETY PLAN CORKTOWN DEVELOPMENT – AREA 4 1336 AND 1342-1350 BAGLEY STREET DETROIT, WAYNE COUNTY, MICHIGAN

1.0 INTRODUCTION

The purpose of this site Health and Safety plan is to establish minimum requirements for the protection of The Traverse Group's employees involved in soil and groundwater sampling activities at the Corktown Development – Area 4 site located in Detroit, Wayne County, Michigan.

In this Health and Safety plan, designed specifically for the Corktown Area 4 site, The Traverse Group intends to satisfy the requirements established by the Michigan Department of Public Health Rule 325.52101-52137, Hazardous Waste Operations and Emergency Response and 29 CFR 1910.120. The Traverse Group personnel involved in the project will be familiar with the plan and agree to follow the sections that pertain to their specific job function(s).

2.0 SITE DESCRIPTION

The Corktown Development – Area 4 site is located in the vicinity of the intersection of Bagley and 8th Streets in Detroit, Michigan. A Site Location Map is included on Page iii. The areas of potential contamination are located throughout the property.

2.1 Chemical and Physical Hazards

Health and safety information regarding hazardous chemicals potentially present at the site is summarized in Table 1. Possible physical hazards associated with the investigative activities include subsurface utilities. The Traverse Group will contact Miss Dig to mark subsurface utilities supplied to the subject property prior to any subsurface activities. No heavy equipment will be used within 5 feet of a subsurface utility marker. If drilling or excavating must take place within 5 feet of a subsurface utility, the utility line will be located by hand digging in that area.

2.2 Affected Area

See Site Location Map.



| | n and Safety Plan own Development – Area 4, Detroit, Wayne County, Mic | Page higan October 24, 200 | |
|---------------------------------|---|---|--|
| 3.0 | ON-SITE ORGANIZATION AND COOR | DINATION | |
| Follo activ | owing is a list of personnel from The Travelities | rse Group who are responsible for on-site | |
| | | | |
| | The Traverse Group (313) 871-5800 | | |
| | Project Manager | Michael K. Jordan | |
| | Project Technical Leader | David McMahon | |
| | Project Team Members | Deanna Pietrzak, Chris Parker | |
| | Health and Safety Coordinator | James C. Fox | |
| | Site Safety Officer(s) | Deanna Pietrzak, Chris Parker | |
| 4.0 | PERSONNEL TRAINING | | |
| The 7 | Fraverse Group's on-site personnel have receive | d 40-hours of safety training and appropriat | |
| 8-hou | ir refresher training as required by Michigan D | epartment of Public Health Rule 325.52101 | |
| 5213 | 7, Hazardous Waste Operations and Emergency | Response and 29 CFR 1910.120. | |
| 5.0 | SITE CONTROL | | |
| On-si | ite personnel from The Traverse Group will o | only be responsible for site control into th | |
| imme | ediate area in which The Traverse Group's per | sonnel are actively working. The Travers | |
| Grou | p will relinquish site control responsibilities w | hen engaging in supervisory or observator | |
| roles | of persons other than those employed by The | Traverse Group. Prior to start of any sit | |
| work | , The Traverse Group will conduct a health a | and safety meeting to review The Travers | |
| Grou | p's site control responsibilities with con | ntractors and subcontractors designate | |
| repre | sentatives. The Traverse Group Site Safety O | fficer will conduct a brief health and safety | |
| "tailg | ate" meeting to review site control response. | | |
| The ' | Traverse Group's employees will not be res | ponsible for equipment and operations o | |
| contractors and subcontractors. | | | |



The Traverse Group will coordinate access control on the site during construction activities and conduct a Health and Safety meeting prior to the start of work.

The site will be divided into three areas: the exclusion zone, the contamination reduction zone, and the support zone.

5.1 Exclusion Zone

The area surrounding each work location will be referred to as the exclusion zone. Only personnel involved with the specific activity taking place will be allowed to enter the exclusion zone. The radius of the exclusion zone for drilling is defined as either 1.5 times the height of the drill rig mast or those areas where the ambient air concentrations exceed those described in Section 6.0, whichever is greater.

5.2 Contamination Reduction Zone

The contamination reduction zone is defined as the area outside the exclusion zone where decontamination activities will take place. The decontamination station will be placed up-wind of the exclusion zone.

5.3 Support Zone

The support zone is defined as the area surrounding the contamination reduction zone where vehicles and equipment will be stationed.

6.0 ENVIRONMENTAL MONITORING

A photo-ionization detector (PID) will be used to continuously screen the breathing zone of The Traverse Group's employees involved in site activities. If a strong hydrocarbon odor leads to a PID reading of 5 ppm or greater, work should be halted and personnel and equipment should be removed from the area promptly. Workers in the exclusion zone must wear the appropriate protective equipment as outlined in Section 7.1 below. Should activity or environmental monitoring require use of alternative PPE other than that described in Section 7.1; the Safety Coordinator will be contacted and advised of the situation. Activity will cease until the Safety Coordinator makes recommendations as to any new changes with regards to operational



| | and Safety Plan wn Developmen | t – Area 4, Detroit, Wayne County, Michigan | Page 4 October 24, 2005 | | | | |
|--------|--|---|----------------------------|--|--|--|--|
| proce | dures and equ | ipment as well as both use of PPE and decontamination | on procedures. Any on- | | | | |
| site p | ersonnel exhi | biting signs of chemical exposure will receive medical | al evaluation. The site | | | | |
| health | and safety p | plan will be revised as needed to reflect changes in | concentrations of the | | | | |
| chemi | icals detected | at the site. | | | | | |
| 7.0 | PERSONA | L PROTECTIVE EQUIPMENT | | | | | |
| Durin | g drilling as | nd system operation and maintenance activities, | personnel in the site | | | | |
| invest | igation area v | vill be equipped with Level D protection as defined in t | he following section. | | | | |
| 7.1 | Exclusion 2 | Zone | | | | | |
| Level | D protection | on has been designated for the exclusion zone | e during boring and | | | | |
| soil/g | roundwater sa | mpling. Specific PPE for Level D protection is listed by | pelow: | | | | |
| o | Hard Hat | | | | | | |
| 0 | Safety Glass | Safety Glasses | | | | | |
| • | Hearing Pro | tection (during oversight of drilling or excavation activ | rities) | | | | |
| 0 | Boots, Steel | Toe | | | | | |
| 0 | (Inner Gloves), Latex; (Outer) Gloves, Polyvinyl Alcohol, Nitrile or other Polychlorinated Biphenyls (PCBs) - resistant equivalent | | | | | | |
| 7.2 | Contamina | tion Reduction Zone | | | | | |
| Level | D protection | has been designated for the contamination reduction 2 | zone. Specific PPE for | | | | |
| | _ | is in Section 7.1. | • | | | | |
| Decor | itamination st | ations will follow the procedure order listed below: | | | | | |
| | Station 1: | Equipment decontamination | | | | | |
| | Station 2: | Outer glove wash and rinse | | | | | |
| | Station 4: | Outer glove removal | | | | | |
| | Station 5: | Inner glove wash and rinse | | | | | |
| | Station 6: | Inner glove removal | | | | | |



Station 7: Wash hands

Disposable safety equipment and spent decontamination solution will be containerized in DOTapproved containers and will be disposed of properly.

7.3 Support Zone

Level D protection has been designated for the support zone. Specific PPE for Level D protection is in Section 7.1.

8.0 EMERGENCY PROCEDURES

In an emergency, on-site personnel will use the following standard emergency procedures. The Traverse Group site safety officer will be notified of any on-site emergencies involving a Traverse Group Employee and must ensure that the appropriate procedures are followed.

Personal injury of a Traverse Group employee in the exclusion zone will initiate the following actions.

- 1. Personnel will assemble in the support zone. If a self-contained breathing apparatus was in use, personnel will assemble at the decontamination line.
- 2. The site safety officer will evaluate the nature of the injury before moving the victim to the support zone. If the nature of the injury is such that moving the victim will not compound the problem or jeopardize the rescuers, the victim will be moved to the support zone.
- 3. If required, a rescue team will enter the exclusion zone.
- 4. An ambulance will be summoned if necessary.

Personal injury of a Traverse Group employee in the support zone will initiate the following actions.

1. The site safety officer will assess the situation; and if the injured person's condition does not affect the operation, work will continue.



- 2. If the injured person's condition increases the risk of injury to others on-site, all personnel will proceed to the decontamination line (if necessary).
- 3. Site activities will stop until the hazard that caused the injury is reduced to a safe level.
- 4. An ambulance will be summoned if necessary.

The following actions will be taken if there is a PPE failure.

- 1. The affected person will leave the exclusion zone.
- 2. Decontamination and medical evaluation will take place.
- 3. Re-entry will not be permitted until the affected PPE is repaired or replaced.

When an on-site emergency requires evacuation of the exclusion zone, personnel will not re-enter until the following are met:

- 1. The conditions that caused the emergency have been corrected.
- 2. The hazards have been reassessed.
- 3. The site safety plan is revised to reflect any changes in the conditions of the site.
- 4. Site personnel have been briefed on any changes in the site safety plan.



| Health and Safety Plan <u>Corktown Development - Area 4, Detroit, Ways</u> | ne County, Michigan | Pag October 24, 20 |
|--|-----------------------------------|-----------------------|
| 9.0 ACKNOWLEDGMENT | | |
| The undersigned acknowledge that they | have reviewed the October 24, 200 | 95 Health and Safety |
| Plan for the Corktown Development – A | | • |
| | | |
| Name (print) | Signature | Date |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |






TABLE 1 CHEMICAL HAZARD SUMMARY

| | TABLE 1 CHEMICAL HAZARD SUMMARY | | | | |
|----------------------------------|------------------------------------|--|--|--|--|
| Chemical | Exposure Limits | Routes of Entry | Symptoms of Exposure | | |
| | ; | VOCs | | | |
| Acrylonitrile* | 2 ppm | Inhalation, absorption, ingestion, skin and/or eye contact | Asphyxia; irritated eyes; headache; sneezing; nausea, vomiting; weakness, light-headedness; skin vesiculation; scaling dermatitis | | |
| Benzene* | 10 ppm | Inhalation, absorption, ingestion, skin and/or eye contact | Irritation of the eyes, nose and respiratory system; giddiness; headache nausea; staggered gait; anorexia; lassitude; dermatitis; bone marrow depression | | |
| Bromochloromethane | 200 ppm | Inhalation, Ingestion, Skin and/or eye contact | Disorientation, dizziness; irritated eyes, throat, skin; pulmonary edema | | |
| Bromodichloromethane | NA_ | NA. | NA NA | | |
| Bromoform | 0.5 ppm | Inhalation, Absorption, Ingestion | Irritated eyes, respiratory system; centra nervous system depression; liver damage | | |
| Bromomethane | NA | NA | NA | | |
| 2-Butanone (MEK) | 200 ppm | Inhalation, Ingestion, Skin and/or eye contact | Irritated eyes, nose; headache; dizziness vomiting | | |
| Carbon Disulfide | 4 ppm | Inhalation, Absorption, Ingestion, Skin and/or eye contact | Dizziness, headache, poor sleep, fatigue nervousness, anorexia, weight loss; psychosis; polyneuropathy; Parkinson- like syndrome; ocular changes; coronar heart disease; gastritis; kidney, liver damage; eye, skin burns; dermatitis | | |
| Carbon Disulfide | . 4 ppm | Inhalation, Absorption, Ingestion, Skin and/or eye contact | Dizziness, headache, poor sleep, fatigue nervousness, anorexia, weight loss; psychosis; polyneuropathy; Parkinson- like syndrome; ocular changes; coronar heart disease; gastritis; kidney, liver | | |
| Carbon Tetrachloride* | 2 ppm | Inhalation, Absorption, Ingestion, Skin and/or eye contact | damage; eye, skin burns; dermatitis Central nervous system depression; nausea, vomiting; liver, kidney damage skin irritation | | |
| Chlorobenzene | 75 ppm | Inhalation, Ingestion, Skin and/or eye contact | Irritated skin, eyes, nose; drowsiness, incoherence; in animals: liver, lung, kidney damage | | |
| Chloroethane | NA NA | NA | NA | | |
| Chloroform* | 2 ppm | Inhalation, Ingestion, Skin and/or eye contact | Dizziness, mental dullness, nausea, disorientation; headache, fatigue; anesthesia; hepatomegaly; irritated eyes skin | | |
| Chloromethane | NA | NA | NA - | | |
| Dibromochloromethane | NA | NA | ŅĀ | | |
| 1,2-Dibromo-3- chloropropane* | 0.001 ppm | Inhalation, Skin and/or eye contact | Drowsiness; nausea, vomiting; irritated eyes, nose, throat, skin; pulmonary edema | | |
| Dibromomethane | NA | . NA | NA . | | |
| 1,2-Dibromoethane | NA | NA | NA | | |

Information obtained from the 1990 NIOSH Pocket Guide to Chemical Hazards and the Columbia Online Information Network.

ppm: parts per million
*: carcinogenic compound

NA: data not available

| TABLE 1 CHEMICAL HAZARD SUMMARY | | | | |
|------------------------------------|--------------------|---|--|--|
| Chemical | Exposure Limits | Routes of Entry | Symptoms of Exposure | |
| 1,2-Dichlorobenzene | 50 ppm | Inhalation, Absorption, Ingestion, Skin and/or eye contact | Irritated nose, eyes; liver, kidney damage; skin blistering | |
| 1,3-Dichlorobenzene | NA | NA | NA | |
| 1,4-Dichlorobenzene* | 75 ppm | Inhalation, Ingestion, Skin and/or eye contact | Headache; eye irritation, periorbital swelling; profuse rhinitis; anorexia, nausea, vomiting; weight loss | |
| 1,4-Dichloro-2-butene (trans) | NA | NA | NA | |
| Dichlorodifluoromethane | 1000 ppm | Inhalation, Skin and/or eye contact | Dizziness, tremors, unconsciousness, cardiac arrhythmias, cardiac arrest | |
| 1,1-Dichloroethane | 100 ppm | Inhalation, Ingestion, Skin and/or eye contact | Central nervous system depression; skin irritation; liver, kidney damage | |
| 1,2-Dichloroethane | NA | NA | NA | |
| 1,1-Dichloroethene | NA | NA | NA | |
| 1,2-Dichloroethene | NA | NA | NA _. | |
| 1,2-Dichloroethene (cis) | NA | NA | NA | |
| 1,2-Dichloroethene (trans) | NA | NA | NA | |
| 1,2-Dichloropropane | NA | NA | _ NA | |
| 1,2-Dichloropropene (cis) | NA | NA | NA | |
| 1,2-Dichloropropene (trans) | NA | NA | NA | |
| Diethyl ether | NA | NA | NA | |
| 1,4-Dioxane | 100 ppm (TWA) | Inhalation, Skin adsorption, Ingestion, Skin and/or eye contact | Irritation eyes, skin nose, throat; drowsiness, headache; nausea, vomiting; liver damage; kidney failure | |
| Ethylbenzene | 100 ppm | Inhalation, Ingestion, Skin and/or eye contact | Irritation of the eyes and mucous membranes; headache; dermatitis; coma; narcosis | |
| Hexachloroethane* | 1 ppm | Inhalation, Absorption, Ingestion, Skin and/or eye contact | Irritation of the eyes | |
| 2-Hexanone | 5 ppm | Inhalation, Absorption, Ingestion, Skin and/or eye contact | Irritated eyes, nose; peripheral neuropathy; weakness, paresthesia; dermatitis; headache; drowsiness | |
| Isopropylbenzene | NA | NA | NA | |
| Methylene Chloride* | 500 ppm | Inhalation, Ingestion, Skin and/or eye contact | Fatigue, weakness, sleepiness, light-headedness; limbs numb, tingle; nausea; irritated eyes, skin | |
| Methyl Iodide* | 2 ppm | Inhalation, Absorption, Ingestion, Skin and/or eye contact | Nausea, vomiting; vertigo, ataxia; slurred speech, drowsiness; dermatitis; eye irritation | |
| 2-Methylnaphthalene | NA | NA | NA | |
| 4-Methyl-2-Propanone (MIBK) | NA | NA | NA NA | |
| Methyl Tertiary Butyl Ether (MTBE) | NA | NA NA | NA | |

Information obtained from the 1990 NIOSH Pocket Guide to Chemical Hazards and the Columbia Online Information Network.

ppm. parts per million

*: carcinogenic compound

NA: data not available

| | CH. | TABLE 1 EMICAL HAZARD SUMMA | ARÝ |
|---|--------------------|--|--|
| Chemical | Exposure Limits | Routes of Entry | Symptoms of Exposure |
| Naphthalene | 10 ppm | Inhalation, Absorption, Ingestion, Skın and/or eye contact | Eye irritation; headache; confusion, excitement, malaise; nausea, vomiting abdominal pain; irritated bladder; profuse sweating; jaundice; hematopoietic, hemoglobinuma, renal shutdown; dermatitis |
| 2-Propanone (acetone) | 750 ppm | Inhalation, Ingestion, Skin and/or eye contact | Irritated eyes, nose, throat; headache, dizziness; dermatitis |
| n-Propylbenzene | NA | NA | NA . |
| Styrene | 50 ppm | Inhalation, Ingestion, Skin and/or eye contact | Irritated eyes, nose; drowsiness, weak unsteady gait; narcosis; defatting dermatitis |
| 1,1,1,2-Tetrachloroethane | NA | NA | NA |
| 1,1,2,2- Tetrachloroethane* | 1 ppm | Inhalation, Absorption, Ingestion, Skin and/or eye contact | Nausea, vomiting, abdominal pain; finger tremors; jaundice, enlarged tend liver; dermatitis; monocytosis; kidney damage |
| Tetrachloroethene | 100 ppm (TWA) | Inhalation, Skin Absorption, Ingestion, Skin and/or eye contact | Irritation eyes, skin, nose, throat, respiratory system; nausea; flush face neck; vertigo, dizziness, incoordination headache, somnolence; skin erythema liver damage |
| Toluene | 100 ppm | Inhalation, Absorption, Ingestion, Skin and/or eye contact | Fatigue, weakness; confusion, euphori dizziness; headache; dilated pupils; lacrimation; nervousness; muscle fatigue; insomnia; paresthesia; dermati |
| 1,1,1-Trichloroethane 1,2,4-Trichlorobenzene | NA NA | NA NA | NA |
| 1,1,2-Trichloroethane* | 10 ppm | Inhalation, Absorption, Ingestion, Skin and/or eye contact | Irritated nose, eyes; central nervous system depression; liver, kidney dama |
| Trichloroethene* | 50 ppm | Inhalation, Ingestion, Skin and/or eye contact | Headache, vertigo; visual disturbance tremors, somnolence, nausea, vomiting irritated eyes; dermatitis; cardiac arrhythmias, paresthesia |
| Trichlorofluoromethane | NA | NA . | NA |
| 1,2,3-Trichloropropane* | 10 ppm | Inhalation, Absorption, Ingestion, Skin and/or eye contact | Irritated eyes, throat; central nervous system depression; liver injury; skin irritation |
| 1,2,4-Trimethylbenzene | . NA | NA | NA NA |
| 1,3,5-Trimethylbenzene | NA . | NA NA | NA |
| Vinyl acetate | NA NA | NA NA | NA NA |
| Vinyl chloride* | 1 ppm | Inhalation | Weakness; abdominal pain, gastrointestinal bleeding; hepatomegal |
| | | | pallor or cyanosis of extremities |
| Xylenes (o,m & p) | 100 ppm | Inhalation, Absorption, Ingestion, Skin and/or eye contact | Dizziness; excitement; drowsiness, incoordination staggering gait; irritation of the eyes, nose and throat; corneal vacuolization; anorexia, nausea, voiniting, abdominal pain; dermatitis |

Information obtained from the 1990 NIOSH Pocket Guide to Chemical Hazards and the Columbia Online Information Network.

ppm. parts per million

*: carcinogenic compound

NA: data not available

| • | | TABLE 1 CHEMICAL HAZARD SUMMARY | | |
|----------|----------------------------|--|---|--|
| Chemical | Exposure Limits | Routes of Entry | Symptoms of Exposure | |
| | · | Metals | Ulceration of nasal septum; derma | |
| Arsenic | 0.010 mg/m ³ | Inhalation, absorption, ingestion, skin and/or eye contact | gastrointestinal disturbances; perip neuropathy; respiratory irritation hyperpigmentation of skin | |
| Barıum | 0.5 mg/m ³ | Inhalation, ingestion, skin and/or eye contact | Irritation of eyes, skin, upper respi system; skin burns; gastroenteri muscle spasm; slow pulse; extrasys hypokalemia | |
| Cadmium* | 0.2 mg/m ³ | Inhalation, Ingestion | Pulmonary edema, dyspnea, cough, tightness, substernal pain; headac chills, muscle aches; nausea, vomi diarrhea; anosmia, emphysema proteinuria, mild anemia | |
| Chromium | 1 mg/m ³ | Inhalation, Ingestion | Histologic fibrosis of the lung | |
| Copper | 1 mg/m³ | Inhalation, Ingestion, Skin and/or eye contact | Irritation of eyes, nose, pharynx; r perforation; metallic taste; dermati animals: lung, liver, kidney dama anemia | |
| Lead | 0.05 mg/m³ | Inhalation, Ingestion, Skin and/or eye contact | Weakness, lassitude, insomnia; fa pallor; pal eye, anorexia, weight l malnutrition; constipation, abdom pain, colic; anemia; gingival lead tremor; wrist paralysis, ankles encephalopathy; nephropathy; irrieyes; hypotension | |
| Mercury* | 0.1 mg/m ³ | Inhalation, absorption, ingestion, skin and/or eye contact | Irritation of eyes, skin; cough; cl pain; dyspnea; bronchitis; pneumo tremor; insomnia; ırritability; indec headache; fatigue; weakness; stom salivation; gastrointestinal disturba | |
| | | | anorexia; weight loss; proteinus Irritation of eyes, skin, nose, thro | |
| Selenium | 0.2 mg/m ³ | Inhalation, ingestion, skin and/or eye contact | visual disturbance; headache; chi fever; dyspnea, bronchitis; metallic garlic breath, gastrointestinal disturbance; dermatitis; eye, skin b in animals: anemia; liver necros cirrhosis; kıdney, spleen damag | |
| Silver | 0.01 mg/m ³ | Inhalation, ingestion, skin and/or eye contact | Blue-gray eyes; nasal septum, thr skin irritation, skin ulceration; gastrointestinal disturbance | |
| Zinc* | 5 mg/m³ | Inhalation | Metal fume fever: chills, muscle a nausea, fever, dry throat, cough weakness, lassitude; metallic tas headache; blurred vision; low back vomiting; fatigue; malaise; tight cl dyspnea, rales, decreased pulmon function | |

Information obtained from the 1990 NIOSH Pocket Guide to Chemical Hazards and the Columbia Online Information Network.

ppm· *. NA: parts per million carcinogenic compound data not available

| TABLE 1 CHEMICAL HAZARD SUMMARY | | | | | | |
|---------------------------------|------------------------------|--|--|--|--|--|
| Chemical | Exposure Limits | Routes of Entry | Symptoms of Exposure | | | |
| Polynuclear Aromatics (PNAs) | | | | | | |
| Acenaphthene | NA | Inhalation, Absorption and Ingestion | Tightness and pain in chest; coughing; difficulty breathing; skin and eye irritation | | | |
| Anthracene | NA | Inhalation, Absorption and Ingestion | Irritation to eyes, nose, throat, and lungs | | | |
| Benzo (a) anthracene | NA | NA | NA | | | |
| Benzo (b) fluoranthene | NA | NA | NA · | | | |
| Benzo (k) fluoranthene | NA | NA | NA | | | |
| Benzo (a) pyrene | NA | NA | NA | | | |
| Benzo (g,h,i) perylene | NA | NA | NA | | | |
| Chrysene | NA | NA | NA | | | |
| Dibenzo (a,h) anthracene | NA | NA | NA | | | |
| Fluoranthene | NA | NA | NĀ | | | |
| Fluorene | NA | NA | NA | | | |
| Ideno (1,2,3-cd) pyrene | NA | NA | NA | | | |
| Naphthalene | 10 ppm | Inhalation, Absorption, Ingestion, Skin and/or eye contact | Eye irritation; headache; confusion, excitement, malaise; nausea, vomiting, abdominal pain; irritated bladder; profuse sweating; jaundice; hematopoietic, hemoglobinuria, renal shutdown; dermatitis | | | |
| Phenanthrene | NA | NA | NA - | | | |
| Pyrene | NA | NA | NA | | | |
| - | | Polychlorinated Biphenyls | | | | |
| Arochlor 1016 | NA | NA | NA | | | |
| Arochlor 1242* | l mg/m³ (skin) | Inhalation, ingestion absorption, skin and/or eye contact | eye irritation; chloracne; liver damage | | | |
| Arochlor 1248 | NA | NA | NA | | | |
| Arochlor 1254* | 0.5 mg/m ³ (skin) | Inhalation, ingestion absorption, skin and/or eye contact | eye and skin irritation; acne-form dermatitis; carcinogen; in animals: liver damage | | | |
| Arochlor 1260 | NA | NA | NA | | | |
| Arochlor 1268 | NA | NA | NA | | | |

Information obtained from the 1990 NIOSH Pocket Guide to Chemical Hazards and the Columbia Online Information Network.

ppm: parts per million

*: carcinogenic compound

NA: data not available